Pay in 4 interest-free payments of $5.99 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Safety depends on the individual, the product source, the formulation, and the route of administration
Synergistic anti-leukemic activity with combination of FLT3 inhibitor quizartinib and MDM2 inhibitor milademetan in FLT3-ITD mutant/p53 wild-type acute myeloid leukemia models
PMCID: PMC10885928
3 AshrafS.ChaB
Orgel JPRO, Persikov AV, Antipova O
Filoviruses in bats: current knowledge and future directions
US$ 25.31
US$ 21.66
US$ 29.20
US$ 25.14
US$ 23.94
US$ 20.36
US$ 23.03
US$ 22.25
